A new expression of immune checkpoint inhibitors’ renal toxicity: when distal tubular acidosis precedes creatinine elevation

Xavier Charmetant 1, Cécile Teuma1,2, Jennifer Lake3, Frédérique Dijoud4, Vincent Frochot5 and Abbas Deeb1

1Department of Nephrology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France, 2Immunology Cancer Research (ImmuCare), Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France, 3Institute of Physiology, University of Zurich, Zürich, Switzerland, 4Department of Pathology, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France and 5Department of Physiology, Hôpital Tenon, APHP, Paris Cedex 20, France

Correspondence and offprint requests to: Xavier Charmetant; E-mail: xaviercharmetant@hotmail.com

ABSTRACT

The main manifestation of acute interstitial nephritis (AIN) due to immune checkpoint inhibitors is acute kidney injury. We report here a biopsy-proven AIN revealed by tubular acidosis. This case highlights that immune checkpoint inhibitor prescribers must be aware of electrolytic disorders since tubular dysfunction can precede serum creatinine increase and reveal renal toxicity.

Keywords: distal tubular acidosis, immune checkpoint inhibitors, nephrotoxicity

BACKGROUND

Renal toxicity of immune checkpoint inhibitors is rare and mainly concerns tubulointerstitial disorders. Several cases have been reported in which acute interstitial nephritis (AIN) was revealed by an acute kidney injury (AKI) [1]. Renal tubular acidosis with AKI has been described, but not biopsy-proven [2]. We report here a biopsy-proven case of renal toxicity as an isolated distal tubular acidosis.

CASE REPORT

A 59-year-old man was hospitalized for metabolic acidosis. He had no medical history except for a Stage IV bronchopulmonary cancer, treated in first line by cisplatin and pemetrexed. Because of Programmed cell death-ligand 1 (PD-L1) over-expression in the tumour, an immune checkpoint inhibitor targeting PD-1 was initiated as a second line (five nivolumab injections, 3 mg/kg/15 days and a single injection of pembrolizumab 2 mg/kg). His baseline serum creatinine (Scr) was 55 μmol/L with normal estimated glomerular filtration rate at 108 mL/min/1.73 m². Baseline serum bicarbonate and potassium were normal. After the sixth administration (Figure 1), he presented with fever and a maculopapular rash on the back. He did not report arthralgia or systemic dryness, and had no digestive troubles. Serum electrolytes showed an uncompensated metabolic hyperchloremic acidosis with hypokalaemia without AKI: serum bicarbonate 11 mmol/L, chloride 113 mmol/L, potassium...
3.3 mmol/L, pH 7.29, pCO₂ 21.8 mmHg and SCR 76 μmol/L. Urine anion gap was positive (+36 mEq/L) with an urine pH of 6. The initial urinary Na/K ratio was inferior to one. There was no proximal tubular disorder (no aminoaciduria, glycosuria or hypophosphataemia). Low tubular proteinuria was found (0.45 g/24 h of low molecular weight proteins) without leucocyturia or haematuria. The diagnosis of distal tubular acidosis was considered. Immunological tests were normal: no autoantibodies (antinuclear antibodies, anti-Ro/SSA, anti-La/SSB, anti-neutrophil cytoplasmic antibodies), complement not consumed (C3 1.92 g/L, C4 0.38 g/L, CH50 95 U/mL) and negative hepatitis B virus, hepatitis C virus and human immunodeficiency virus serologies. Renal ultrasonography was normal. Kidney biopsy (Figure 2) showed an interstitial oedematous fibrosis of 30–40% of the cortex with mononucleated cell infiltration (lymphocytes (CD4⁺ > CD8⁺), macrophages and rare eosinophils). Tubulitis affected exclusively distal convoluted tubules and collecting ducts Supplementary data, Figure S1. Spectrophotometry identified monohydrated calcium oxalate crystals in some subcapsular tubes (Figure 3). Immunofluorescence analysis of the patient’s serum (dilutions 1:100 and 1:500) on control kidneys (human and rat) did not reveal any specific signal. The immune
checkpoint inhibitor was stopped. Oral sodium bicarbonate alone was first given for 1 week and did not significantly improve acidosis. Then corticosteroids of 1 mg/kg/day were initiated: clinical symptoms disappeared and serum bicarbonate increased (Figure 1).

DISCUSSION

Among the renal immune-related adverse events, tubular acidosis is not exceptional. Two cases have been reported in which AKI was associated with hypokalaemia and metabolic acidosis [2]. We report the first case of renal toxicity revealed by isolated renal tubular acidosis without AKI. We provide a histological proof of isolated lesions of distal convoluted tubules. We also show additional crystals of monohydrated calcium oxalate by infrared spectrophotometry, probably secondary to hypokalaemia. The current Common Terminology Criteria for Adverse Events (fifth version) only consider SCR increase for renal toxicity. This case strengthens the fact that oncologists and nephrologists should be aware that tubular dysfunction could be the first sign of an immune checkpoint inhibitor-induced AIN, even in the absence of AKI.

Acquired distal tubular acidosis results from an alteration of $\text{H}^+\text{-ATPase}$ or $\text{Cl}^-/\text{HCO}_3^-$ pump in type A intercalated cells in collecting duct, of which autoimmunity is a frequent cause. In Sjögren’s syndrome, it has been proven that autoantibodies isolated from patients interact directly with one of these pumps [3]. We did not identify autoantibodies in our patient’s serum, but de novo organ-specific autoantibodies are rarely found under immune checkpoint inhibitors. If immune-related adverse events with systemic manifestations are more frequent in patients with pre-existing autoimmune disease, patients without autoimmune disease develop isolated organ lesions [4], as in the present case.

The PD-1/PD-L1 pathway is a late checkpoint that downregulates activated T lymphocytes. In the kidney during an inflammation condition, tubular epithelial cells increase PD-L1 expression as a protective mechanism [5]. Because PD-1/PD-L1 is non-specific of anti-tumour activity, immune checkpoint inhibitors allow a response directed against the own recipient’s organs. In the present case, this may explain the lymphocyte infiltrate and the sensitivity to corticosteroids. As lymphocytes affected exclusively distal tubular epithelial cells in our case, we postulate that distal and proximal tubular epithelial cells have a different arsenal of lymphocytic receptor ligands, and this difference imparts an immunological privilege to the proximal tubular epithelial cells during immune checkpoint inhibitors treatment. In conclusion, distal tubular acidosis can be an isolated symptom of AIN induced by immune checkpoint inhibitors and must be known by oncologists and nephrologists.

SUPPLEMENTARY DATA

Supplementary data are available at ckj online.
ACKNOWLEDGEMENTS
The authors would like to thank Marie-Nathalie Kolopp-Sarda, MD, from the Department of Immunology, CHU Lyon Sud; Meghann Antoine and the other members of the Nephrology Department, CHU Lyon Sud; Guglielmo Schiano, from the Institute of Physiology, University of Zurich; Maurice Pérol, MD, from the Centre Léon Bérard, Lyon, for the help with patient management; and Denis Fouque, MD, PhD, from the Nephrology Department, CHU Lyon Sud, for his help in writing the manuscript.

CONFLICT OF INTEREST STATEMENT
None declared. The results presented in this paper have not been published previously in whole or part, except in abstract format.

REFERENCES
1. Wanchoo R, Karam S, Uppal NN et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 2017; 45: 160–169
2. El Bitar S, Weerasinghe C, El-Charabaty E et al. Renal tubular acidosis an adverse effect of PD-1 inhibitor immunotherapy. Case Rep Oncol Med 2018; 2018: 8408015
3. Devuyst O, Lemaire M, Mohebbi N et al. Autoantibodies against intercalated cells in Sjögren’s syndrome. Kidney Int 2009; 76: 229
4. Danlos F-X, Voisin A-L, Dyevre V et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 2018; 91: 21–29
5. Starke A, Lindenmeyer MT, Segerer S et al. Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. Kidney Int 2010; 78: 38–47